Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

2016423 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Haematology

Volume 3, Issue 4, pp. e196-e204

Field-Weighted Citation Impact: 29.82